Andere Sprachen Astellas Pharma Inc. OTC Markets

Aktien

A0YGQP

US04623U1025

ALPMY

Verzögert OTC Markets Andere Börsenplätze 21:29:34 21.06.2024			% 5 Tage	% 1. Jan.
9,538 ^USD	+1,58 %		+0,36 %	-19,80 %

21.05.	Astellas kündigt Zusammenarbeit mit YASKAWA an, um ein innovatives Zelltherapie-Ökosystem durch die Integration von Pharma- und Robotik-Technologien zu schaffen	CI
08.05.	Astellas eröffnet neues, hochmodernes 90-Millionen-Dollar-Innovationszentrum an der Westküste im Biotech-Korridor von South San Francisco	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	03.06.
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date	31.05.
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies	21.05.
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	16.05.
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	08.05.
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	02.05.
Malin Corp investee signs agreement with Astellas Pharma	01.05.
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	01.05.
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	30.04.
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024	25.04.
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024	25.04.
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	25.04.
Astellas Pharma Inc. Announces Board and Committee Retirements	25.04.
European Commission Approves Astellas Pharma Label Extension for Xtandi	25.04.
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	24.04.
Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM	23.04.
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	22.04.
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	22.04.
Lupin Launches Mirabegron Extended-Release Tablets in US	22.04.
Japan Inc makes a renewed U.S. push as China fears mount	17.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Astellas Pharma Inc. OTC Markets

Aktien

A0YGQP

US04623U1025

ALPMY

Andere Sprachen

Filter